- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Formycon Announces Positive Interim Data for Ranibizumab Biosimilar
Formycon and its licensee Bioeq today announced positive interim results for a phase 3 clinical trial of FYB201, a proposed ranibizumab biosimilar referencing Lucentis, which is an anti–vascular endothelial growth factor therapy approved to treat patients with neovascular age-related macular degeneration.
Formycon and its licensee Bioeq today announced positive interim results for a phase 3 clinical trial of FYB201, a proposed ranibizumab biosimilar referencing Lucentis, which is an anti-vascular endothelial growth factor therapy approved to treat patients with neovascular age-related macular degeneration (nAMD).
According to Formycon, the COLUMBUS-AMD trial, which compared the efficacy of FYB201 of the reference ranibizumab in patients with nAMD, reached its primary efficacy endpoint, measuring the change in best corrected visual acuity after 8 weeks. The confidence interval, says the drug maker, lies within the pre-specified equivalence margin, and the study has not raised any new concerns about safety or immunogenicity.
The final patient in the trial, in which patients are treated for a total of 48 weeks, is expected to complete treatment in the second quarter of 2018. Data from the study will be included in applications for marketing approval in both the United States and Europe.
Thiemo Schreiber, PhD, of Bioeq, said in a statement, “Our aim is the approval and launch of FYB201 as the first biosimilar to Lucentis in the [United States] in 2020 and in the countries of the European Economic Area in 2022. We thus want to offer a larger number of patients more affordable access to this important and highly effective treatment.”
Other companies developing ranibizumab biosimilars include Samsung Bioepis, which began a phase 3 trial of its proposed product, SB11, in 2017. Samsung Bioepis projects that it will have collected its primary outcome data by April of 2019. Additionally, Pfenex, which reassumed rights to PF582 from Pfizer in 2016, has indicated that it may be considering resuming work on its biosimilar candidate after having halted development due to costs and a long development timeline. In April 2018, Pfenex indicated that it was interested in working with a strategic development partner to advance its program.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
